Zydus Lifesciences and Torrent Pharmaceuticals have entered into a licensing an supply agreement to co-market Saroglitazar Mg in India, the companies announced on Friday, November 10. Saroglitazar is used for the treatment of non-alcoholic Steato Hepatitis and Non-Alcoholic Fatty Liver Disease.
Saroglitazar Magnesium, by Zydus, is the only drug approved by approved by the DCGI for NASH and NAFLD in the country. India is the first country to have a drug approved for these conditions.
Under the agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name VORXAR. Zydus launched the drug under the brand names Lipaglyn and Bilypsa. Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.
The drug was initially launched in India for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. Later in 2020, the drug received aprroval for treatment of NASH and NAFLD.
